Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECI-006 in Melanoma
NCT03394937Phase 1Terminated
- Sponsor
- eTheRNA immunotherapies
- Start
- Jun 2017
- Primary completion
- Dec 2020
- Modality
- Prophylactic Vaccines, RNA Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ECI-006 in melanoma (4 cohorts), sponsored by eTheRNA immunotherapies. Primary endpoint: Incidence and severity of treatment-emergent adverse events at 24 weeks. Started Jun 2017; status: terminated.
02
Drugs
ECI-006
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03394937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03394937.